MedTrace Logo

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT03812523 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-04-04

No results posted yet for this study

Summary

A Randomized Phase II study Comparing Lorcaserin versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin

Conditions

  • Chemotherapy-Induced Peripheral Neuropathy

Interventions

DRUG

Duloxetine 60 mg qd

60 mg tablet Taken by mouth, Once Daily for 180 Days

DRUG

Lorcaserin

10 mg tablet Taken by mouth Twice Daily for 180 Days

Sponsors & Collaborators

  • Southeastern Regional Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-30
Primary Completion
2021-02-28
Completion
2021-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03812523 on ClinicalTrials.gov